Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report issued to clients and investors on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Vanda Pharmaceuticals in a research note on Monday, December 23rd.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $4.85 on Friday. Vanda Pharmaceuticals has a 1 year low of $3.46 and a 1 year high of $6.75. The stock has a market capitalization of $282.79 million, a price-to-earnings ratio of -17.32 and a beta of 0.77. The company’s 50 day simple moving average is $4.88 and its 200 day simple moving average is $5.13.

Insider Buying and Selling

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the sale, the director now owns 44,857 shares of the company’s stock, valued at $231,910.69. This trade represents a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Large investors have recently bought and sold shares of the company. Meeder Asset Management Inc. acquired a new position in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $39,000. ORG Wealth Partners LLC bought a new stake in Vanda Pharmaceuticals during the 3rd quarter worth approximately $40,000. China Universal Asset Management Co. Ltd. grew its holdings in Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 4,374 shares during the last quarter. XTX Topco Ltd acquired a new position in Vanda Pharmaceuticals in the 2nd quarter valued at approximately $75,000. Finally, Intech Investment Management LLC bought a new position in shares of Vanda Pharmaceuticals during the third quarter valued at $84,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.